Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Babak Behnam maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There is currently 1 pending office action recorded for this portfolio. This indicates a concentrated prosecution phase, where the company is focusing its resources on a specific pharmaceutical or biotechnological advancement.
The portfolio's active matters are handled by 1 distinct examiner and 1 distinct art unit. This suggests that the technology being patented is highly specialized, requiring review by a specific examination group. The absence of multiple examiners or units means that the prosecution strategy is not fragmented across different parts of the patent office.
FETTEROLF, BRANDON J is the busiest examiner for this portfolio, with 1 busiest examiner pending office action. Because the total number of pending office actions is 1, this examiner is responsible for all current pending matters. The focus on 1 distinct art unit and 1 distinct examiner ensures that the company's current patent prosecution is centralized and consistent.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAHLIN, HEATHER RAQUEL | 1 | 41.1% | +47.5% |
| FETTEROLF, BRANDON J | 1 | 52.0% | +17.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17999434 | Compositions and Methods for Treating Morphine, Heroin, and Alcohol Dependence | FETTEROLF, BRANDON J | 18d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17999434 | Compositions and Methods for Treating Morphine, Heroin, and Alcohol Dependence | FETTEROLF, BRANDON J | 18d overdue |
| 17999441 | Compositions and Methods for Treating Cocaine, Nicotine, and Methamphetamine Dependence | DAHLIN, HEATHER RAQUEL | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17999441 | Compositions and Methods for Treating Cocaine, Nicotine, and Methamphetamine Dependence | DAHLIN, HEATHER RAQUEL | 1629 | §103 | Final Rejection | — | Pending | Nov 21, 2022 |
| 17999434 | Compositions and Methods for Treating Morphine, Heroin, and Alcohol Dependence | FETTEROLF, BRANDON J | 1626 | §102§103 | Non-Final OA | 18d overdue | Pending | Nov 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial